The aim of the present study was to investigate different biological prognostic markers to
identify high‑risk patients with chronic lymphocytic leukemia (CLL) with a higher tumor …

Chronic lymphocytic leukemia (CLL) is characterized by a neoplastic B‐cell population
coexpressing CD5 and CD23; however, the expression of CD23 is variable. In human, two …

Background: Chronic lymphoproliferative disorders (CLPDs) are heterogeneous group of
disorders with variable clinical presentations and outcomes. Therefore, accurate …

Background CD26 is expressed in all chronic myeloid leukemia (CML) patients. This study
investigated the role of CD26+ LSCs in diagnosis and follow up of CML patients. Method …

SUMMARY Background: Chronic Lymphocytic Leukemia (CLL) is one of the most common
diagnoses made by flow cytome-try laboratories. There is no consensus on which markers …

Background: Immunophenotyping has a central role in CLL. However, CLL is a very
heterogenous disease, both morphologically and immunophenotypically; thus, its diagnosis …

Introduction Chronic lymphocytic leukemia (CLL) is a B-cell disorder, but it is also associated
with abnormalities in T-lymphocyte function. In this study we examine changes in T …

B-cell chronic lymphocytic leukemia (B-CLL) is phenotypically characterized by cell surface
coexpression of CD19, CD20, CD5, and CD23. However, the concomitant presence of other …

CD20 is an important therapeutic target in chronic lymphocytic leukaemia (CLL). In order to
examine the relationship between CD20 expression and cytogenetic abnormalities, we …

The human CD8 molecule is usually expressed on T lymphocytes or natural killer cells but
not on normal B cells. Over a course of 5 years, we followed a case of B-CLL which …